2% w/w mupirocin free acid in a white, translucent, water soluble, polyethylene glycol base.
Excipients/Inactive Ingredients: Polyethylene glycol.
Pharmacology: Pharmacodynamics: Mupirocin is a topical antibacterial agent, active against those organisms responsible for the majority of skin infections eg, Staphylococcus aureus including methicillin-resistant strains, other staphylococci and streptococci. It is also active against certain gram-negative pathogens eg, Haemophilus influenzae.
Pharmacokinetics: Absorption: Mupirocin penetrates intact human skin but the rate of systemic absorption appears to be low.
Excretion: Systemically absorbed mupirocin is rapidly metabolised to the inactive metabolite monic acid and quickly excreted by the kidneys.
Bacterial skin infections eg, impetigo, folliculitis and furunculosis.
Adults and Children: Apply to the affected area up to 3 times daily for up to 10 days. The area may be covered with a dressing or occluded if desired.
Hypersensitivity to Mupider or other ointments containing polyethylene glycol and to any of the constituents.
Mupider ointment is not suitable for ophthalmic or intranasal use. Mupider ointment is not formulated for use on mucosal surfaces. When used on the face, care should be taken to avoid the eyes.
Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol-based ointments, Mupider should be used with caution if there is evidence of moderate or severe renal impairment.
Effects on Ability to Drive and Use Machines: No adverse effects on the ability to drive and use machines have been observed.
Adequate human data on use during pregnancy are not available. There is, therefore, inadequate evidence of safety to recommend the use of Mupider during pregnancy. However, studies in experimental animals have shown mupirocin to be without teratogenic effects.
Adequate human and animal data on use during lactation are not available.
Clinical Trials Data: Skin and Subcutaneous Disorders: Burning localised to the area of application. Itching, erythema, stinging and dryness localised to the area of application. Cutaneous sensitisation reactions to mupirocin or the ointment base.
Post-Marketing Experience: Immune System Disorders: Systemic allergic reactions have been reported with Mupider ointment.
Instructions for Use/Handling: Any ointment at the end of the treatment should be discarded.
Incompatibilities: None reported.
D06AX09 - mupirocin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
Mupider oint 2% w/w
15 g x 1's
Sign Out
